Magnetar Financial Cut By $2.69 Million Its Crown Castle Intl New (CCI) Position; 8 Analysts Are Bullish Concert Pharmaceuticals, Inc. (CNCE) Last Week

February 19, 2018 - By Darrin Black

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Concert Pharmaceuticals had 22 analyst reports since August 12, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $30.0 target in Thursday, October 19 report. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. On Monday, November 9 the stock rating was downgraded by UBS to “Neutral”. The firm has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. As per Friday, October 20, the company rating was maintained by H.C. Wainwright. Mizuho maintained the stock with “Buy” rating in Monday, November 6 report. As per Tuesday, September 22, the company rating was maintained by Roth Capital. The firm earned “Buy” rating on Thursday, June 29 by Aegis Capital. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Buy” rating given on Tuesday, September 22 by TH Capital. H.C. Wainwright maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Monday, September 18 with “Buy” rating. See Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) latest ratings:

12/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $27.0 Maintain
12/01/2018 Broker: Mizuho Old Rating: Buy New Rating: Neutral Old Target: $23 New Target: $23 Downgrade
19/12/2017 Broker: UBS Rating: Buy New Target: $34.0 Maintain
10/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $21.0 Maintain
06/11/2017 Broker: Mizuho Rating: Buy New Target: $23.0 Maintain
26/10/2017 Broker: Mizuho Rating: Buy New Target: $23 Initiates Coverage On
19/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $30.0 Maintain
20/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $21.0 Maintain
18/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $20.0 Maintain




Magnetar Financial Llc decreased Crown Castle Intl Corp New (CCI) stake by 53.03% reported in 2017Q3 SEC filing. Magnetar Financial Llc sold 27,189 shares as Crown Castle Intl Corp New (CCI)’s stock rose 11.44%. The Magnetar Financial Llc holds 24,083 shares with $2.41 million value, down from 51,272 last quarter. Crown Castle Intl Corp New now has $44.33B valuation. The stock increased 1.37% or $1.48 during the last trading session, reaching $109.12. About 2.77 million shares traded or 18.60% up from the average. Crown Castle International Corp. (NYSE:CCI) has risen 11.07% since February 19, 2017 and is uptrending. It has underperformed by 5.63% the S&P500.

Among 20 analysts covering Crown Castle International Corp (NYSE:CCI), 13 have Buy rating, 0 Sell and 7 Hold. Therefore 65% are positive. Crown Castle International Corp had 60 analyst reports since July 21, 2015 according to SRatingsIntel. As per Monday, April 25, the company rating was maintained by Cowen & Co. RBC Capital Markets maintained Crown Castle International Corp. (NYSE:REIT) rating on Wednesday, April 19. RBC Capital Markets has “Buy” rating and $107 target. Jefferies maintained it with “Buy” rating and $11000 target in Monday, June 5 report. The firm has “Buy” rating by Stifel Nicolaus given on Friday, May 26. The rating was maintained by Bank of America on Friday, September 8 with “Buy”. Cowen & Co maintained Crown Castle International Corp. (NYSE:REIT) rating on Friday, September 22. Cowen & Co has “Buy” rating and $112.0 target. The company was downgraded on Monday, June 12 by Raymond James. Suntrust Robinson initiated the stock with “Buy” rating in Thursday, February 25 report. The firm has “Neutral” rating by Citigroup given on Monday, August 28. RBC Capital Markets maintained the shares of CCI in report on Wednesday, November 29 with “Buy” rating.

Investors sentiment increased to 1.58 in 2017 Q3. Its up 0.27, from 1.31 in 2017Q2. It increased, as 46 investors sold CCI shares while 172 reduced holdings. 72 funds opened positions while 272 raised stakes. 377.71 million shares or 14.61% more from 329.57 million shares in 2017Q2 were reported. Whittier Trust invested in 809 shares or 0% of the stock. Enterprise Svcs stated it has 0% in Crown Castle International Corp. (NYSE:REIT). Neuberger Berman Ltd Liability has 1.45 million shares. Hollow Brook Wealth Mgmt Ltd Liability Corporation holds 2.46% or 33,630 shares. Rfg Advisory Grp Limited Liability Corp owns 5,177 shares. Pax World Limited Liability Corp holds 181,248 shares or 1.04% of its portfolio. Huntington Bancorporation holds 328,725 shares or 0.55% of its portfolio. Glenmede Tru Na invested 0.02% in Crown Castle International Corp. (NYSE:REIT). Marsico Capital Mgmt Limited Liability Corp accumulated 0.9% or 224,326 shares. Services Automobile Association invested in 0.04% or 144,614 shares. 23,985 are owned by Gamco Invsts Incorporated Et Al. Allen Inv Mgmt Lc stated it has 0.01% of its portfolio in Crown Castle International Corp. (NYSE:REIT). Real Estate Mngmt Ltd Liability Com stated it has 228,800 shares or 4.71% of all its holdings. Sumitomo Mitsui Holdg invested in 0.15% or 1.09 million shares. Washington Tru Fincl Bank invested in 0.01% or 400 shares.

Magnetar Financial Llc increased Schein Henry Inc (NASDAQ:HSIC) stake by 14,098 shares to 20,113 valued at $1.65M in 2017Q3. It also upped Forest City Rlty Tr Inc stake by 360,827 shares and now owns 446,074 shares. Chemours Co was raised too.

Investors sentiment increased to 1.18 in 2017 Q3. Its up 0.05, from 1.13 in 2017Q2. It is positive, as 13 investors sold Concert Pharmaceuticals, Inc. shares while 20 reduced holdings. 17 funds opened positions while 22 raised stakes. 14.57 million shares or 5.31% more from 13.83 million shares in 2017Q2 were reported. Citigroup Inc reported 3,823 shares. Point72 Asset Mgmt Lp invested in 0% or 57,134 shares. Renaissance Technologies Ltd Llc invested in 0.01% or 379,900 shares. Bankshares Of Montreal Can invested 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). D E Shaw & Inc invested in 301,836 shares or 0.01% of the stock. Franklin Resources reported 687,000 shares. 16,200 were reported by New York State Common Retirement Fund. Parametric Portfolio Associates Limited Liability Company holds 0% or 10,616 shares in its portfolio. Dimensional Fund Advsrs L P owns 268,889 shares. Retail Bank Of New York Mellon owns 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 127,724 shares. Credit Suisse Ag has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). First Manhattan holds 0.01% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) or 68,900 shares. Balyasny Asset Mngmt Lc invested in 11,565 shares. Rockefeller Fincl Serv Inc reported 9,533 shares or 0% of all its holdings. Princeton Capital Mgmt stated it has 0.11% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE).

Since September 14, 2017, it had 1 buying transaction, and 6 insider sales for $2.82 million activity. ALDRICH RICHARD sold $597,833 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Tuesday, January 16. Another trade for 3,500 shares valued at $50,785 was made by Lynch Ryan on Thursday, September 14. BVF PARTNERS L P/IL also bought $5.26M worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Thursday, October 19.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.